Literature DB >> 41001

Characterization of anaerobic gram-negative bacilli by using rapid slide tests for beta-lactamase production.

A M Bourgault, J E Rosenblatt.   

Abstract

A total of 175 isolates of anaerobic gram-negative bacilli were tested for beta-lactamase production by using a slide test modification of the chromogenic cephalosporin (Nitrocefin, Glaxo, Middlesex, England) assay and the iodometric slide test. Included isolates were Bacteroides melaninogenicus (46), B. fragilis (78), other Bacteroides isolates (21), Fusobacterium (25), and other gram-negative bacilli (5). Both slide tests detected 25 B. melaninogenicus isolates that were beta-lactamase producers (minimal inhibitory concentration of penicillin was greater than 0.78 micrograms/ml). beta-Lactamase produced by the other gram-negative anaerobes could only be detected by the Nitrocefin assay. This assay was positive in 70 or 77 B. fragilis against which the minimal inhibitory concentration of penicillin was greater than 0.78 micrograms/ml. Ten of 11 other species of Bacteroides against which the minimal inhibitory concentration of penicillin was greater than 0.78 micrograms/ml were also Nitrocefin test positive. Minimal inhibitory concentrations of penicillin against all isolates of Fusobacterium and unidentifified gram-negative bacilli were less than or equal to 0.78 micrograms/ml and were Nitrocefin assay negative. beta-Lactamase-producing strains of B. melaninogenicus can be differentiated because both the slide iodometric and Nitrocefin assays will be positive, whereas beta-lactamase produced by other Bacteroides will only be detected by the Nitrocefin assay. Such penicillin-resistant isolates could be detected and reported to clinicians before final identification.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 41001      PMCID: PMC275374          DOI: 10.1128/jcm.9.6.654-656.1979

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Medium for use in antibiotic susceptibility testing of anaerobic bacteria.

Authors:  T D Wilkins; S Chalgren
Journal:  Antimicrob Agents Chemother       Date:  1976-12       Impact factor: 5.191

2.  Isolation and identification of anaerobic bacteria.

Authors:  J E Rosenblatt
Journal:  Hum Pathol       Date:  1976-03       Impact factor: 3.466

3.  Formation of beta-lactamase in Bacteroides fragilis: cell-bound and extracellular activity.

Authors:  B Olsson; C E Nord; T Wadström
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

4.  Penicillin resistance and penicillinase production in clinical isolates of Bacteroides melaninogenicus.

Authors:  P R Murray; J E Rosenblatt
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

5.  Ampicillin resistance in Haemophilus influenzae as determined by a rapid test for beta-lactamase production.

Authors:  C Thornsberry; L A Kirven
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

6.  A rapid slide test for penicillinase.

Authors:  J E Rosenblatt; A M Neumann
Journal:  Am J Clin Pathol       Date:  1978-03       Impact factor: 2.493

7.  Beta-lactamase activity in anaerobic bacteria.

Authors:  A E Weinrich; V E Del bene
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

8.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

9.  Cephalosporinase activity in Bacteroides fragilis.

Authors:  V E Del Bene; W E Farrar
Journal:  Antimicrob Agents Chemother       Date:  1973-03       Impact factor: 5.191

  9 in total
  13 in total

1.  Effect of selective media on recovery of obligately anaerobic gram-negative rods from human faeces.

Authors:  J G Ruseler-Van Embden; H C Both-Patoir
Journal:  Antonie Van Leeuwenhoek       Date:  1983-11       Impact factor: 2.271

2.  Evaluation of three commercial tests for rapid detection of beta-lactamase in anaerobic bacteria.

Authors:  M LaRocco; A Robinson
Journal:  Eur J Clin Microbiol       Date:  1985-12       Impact factor: 3.267

3.  In vitro activity of cefotaxime against clinically significant pathogens.

Authors:  S Nakashio; M Nakamura
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Susceptibilities of species of the Bacteroides fragilis group to 10 antimicrobial agents.

Authors:  C Betriu; E Campos; C Cabronero; C Rodriguez-Avial; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

5.  Susceptibilities of beta-lactamase-positive and -negative strains of Campylobacter coli to beta-lactam agents.

Authors:  N Lachance; C Gaudreau; F Lamothe; F Turgeon
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

6.  Effect of clavulanic acid on the activities of ten beta-lactam agents against members of the Bacteroides fragilis group.

Authors:  F Lamothe; F Auger; J M Lacroix
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

7.  Identification of a streptomycin resistance gene and a partial Tn3 transposon coding for a beta-lactamase in a periodontal strain of Eikenella corrodens.

Authors:  J M Lacroix; C B Walker
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

8.  Characterization of a beta-lactamase found in Eikenella corrodens.

Authors:  J M Lacroix; C Walker
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

9.  Beta-lactamase-producing isolates of Bacteroides species from children.

Authors:  I Brook; L Calhoun; P Yocum
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

10.  Factors affecting antimicrobial susceptibility of Fusobacterium species.

Authors:  M D Rowland; V E Del Bene; J W Lewis
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.